N
Neil R Poulter
Researcher at Imperial College London
Publications - 458
Citations - 50552
Neil R Poulter is an academic researcher from Imperial College London. The author has contributed to research in topics: Blood pressure & Medicine. The author has an hindex of 76, co-authored 412 publications receiving 45176 citations. Previous affiliations of Neil R Poulter include Wellcome Trust & St Mary's Hospital.
Papers
More filters
Journal ArticleDOI
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Anushka Patel,Stephen MacMahon,John Chalmers,Bruce Neal,Laurent Billot,Mark Woodward,Mark Woodward,Michel Marre,Mark E. Cooper,Paul Glasziou,Paul Glasziou,Diederick E. Grobbee,Pavel Hamet,Stephen B. Harrap,Simon Heller,Lisheng Liu,Giuseppe Mancia,Carl Erik Mogensen,C. Y. Pan,Neil R Poulter,Anthony Rodgers,Bryan Williams,Severine Bompoint,Bastiaan E. de Galan,Bastiaan E. de Galan,Rohina Joshi,F. Travert +26 more
TL;DR: A strategy of intensive glucose control, involving gliclazide (modified release) and other drugs as required, that lowered the glycated hemoglobin value to 6.5% yielded a 10% relative reduction in the combined outcome of major macrovascular and microvascular events, primarily as a consequence of a 21%relative reduction in nephropathy.
Journal ArticleDOI
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Steven P. Marso,Gilbert H. Daniels,Kirstine Brown-Frandsen,Peter Lommer Kristensen,Johannes F.E. Mann,Michael A. Nauck,Steven E. Nissen,Stuart J. Pocock,Neil R Poulter,Lasse Steen Ravn,William M. Steinberg,Mette Stockner,Bernard Zinman,Richard M. Bergenstal,John B. Buse +14 more
TL;DR: In the time-to-event analysis, the rate of the first occurrence of death from cardiovascular causes, nonfatal myocardial infarction, orNonfatal stroke among patients with type 2 diabetes mellitus was lower with liraglutide than with placebo.
Journal ArticleDOI
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial
Peter S. Sever,Björn Dahlöf,Neil R Poulter,Hans Wedel,Gareth Beevers,Mark J. Caulfield,Rory Collins,Sverre E. Kjeldsen,Arni Kristinsson,Gordon T. McInnes,Jesper Mehlsen,Markku S. Nieminen,Eoin O'Brien,Jan Östergren +13 more
TL;DR: The reductions in major cardiovascular events with atorvastatin are large, given the short follow-up time, and may have implications for future lipid-lowering guidelines.
Journal ArticleDOI
Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis.
Kunihiro Matsushita,Marije van der Velde,Brad C. Astor,Mark Woodward,Andrew S. Levey,Paul E. de Jong,Josef Coresh,Ron T. Gansevoort,Meguid El-Nahas,Kai-Uwe Eckardt,Bertram L. Kasiske,Marcello Tonelli,Brenda R. Hemmelgarn,Yaping Wang,Robert C. Atkins,Kevan R. Polkinghorne,Steven J. Chadban,Anoop Shankar,Ronald Klein,Barbara E.K. Klein,Haiyan Wang,Fang Wang,Luxia Zhang,Lisheng Liu,Michael G. Shlipak,Mark J. Sarnak,Ronit Katz,Linda Fried,Tazeen H. Jafar,M. Mazharul Islam,Juanita Hatcher,Neil R Poulter,Nish Chaturvedi,Dietrich Rothenbacher,Hermann Brenner,Elke Raum,Wolfgang Koenig,Caroline S. Fox,Shih-Jen Hwang,James B. Meigs,Massimo Cirillo,Stein Hallan,Stian Lydersen,Jostein Holmen,Paul Roderick,Dorothea Nitsch,Astrid E. Fletcher,Christopher J. Bulpitt,Takayoshi Ohkubo,Hirohito Metoki,Masaaki Nakayama,Masahiro Kikuya,Yutaka Imai,Simerjot K. Jassal,Elizabeth Barrett-Connor,Jaclyn Bergstrom,David G. Warnock,Paul Muntner,Suzanne E. Judd,William M. McClellan,Mary Cushman,George Howard,Leslie A. McClure,Sun Ha Jee,Heejin Kimm,Ji Eun Yun,Chi Pang Wen,Sung Feng Wen,Chwen Keng Tsao,Min Kuang Tsai,Johan Ärnlöv,Priscilla Auguste,Kasper Veldhuis,Laura Camarata,Beverly Thomas,Tom Manley +75 more
TL;DR: In this article, a meta-analysis of general population cohorts was conducted to assess the independent and combined associations of estimated glomerular filtration rate (eGFR) and albuminuria with mortality.
Journal ArticleDOI
Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial
Björn Dahlöf,Peter S. Sever,Neil R Poulter,Hans Wedel,D Gareth Beevers,Mark J. Caulfield,Rory Collins,Sverre E. Kjeldsen,Arni Kristinsson,Gordon T. McInnes,Jesper Mehlsen,Markku S. Nieminen,Eoin O'Brien,Jan Östergren +13 more
TL;DR: The amlodipine-based regimen prevented more major cardiovascular events and induced less diabetes than the atenolol- based regimen, and these effects might not be entirely explained by better control of blood pressure.